Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

VRC 608: A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-EBOMAB092-00-AB (MAb114), Administered Intravenously to Healthy Adults

NCT03478891 is registered in ClinicalTrials.gov with National Institute of Allergy and Infectious Diseases (NIAID) as lead sponsor.

NCT NCT03478891
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03478891 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
VRC 608: A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-EBOMAB092-00-AB (MAb114), Administered Intravenously to Healthy Adults
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Phase
Phase 1
Overall status
Completed
Start date
May 16, 2018
Completion date
March 20, 2019
Enrollment
19 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy adult immune responses to vaccine